Clinical trials: RAS Wild Type
Elderly Metastatic Colorectal Cancer Patients
Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
Few data are available about the treatment of metastatic colorectal cancer (mCRC) elderly patients with anti-EGFR agents in combination with chemotherapy.
- Trial name
- PANDA (NCT02904031)
- Testing
- 5-fluorouracil, oxaliplatin, l-leucovorin
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
In 2018, global cancer incidence reached 18.1 million new cases, with 9.6 million cancer-related deaths. Colorectal cancer ranked as the third most common malignancy by incidence. Data from the U.S.
- Trial name
- NCT06776757
- Testing
- Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Colorectal Cancer
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.
- Trial name
- NCT05619172
- Testing
- Nanrilkefusp alfa, Cetuximab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 16 people
- Sponsor
- SOTIO Biotech AG
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Colorectal Cancer
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Two-part phase 1B clinical trial combining cextuximab and savolitinib for treating Ras wild-type colorectal cancer (CRC). Part 1 will assess the safety and tolerability of this drug combination and will include patients with…
- Trial name
- NCT02630420
- Testing
- cetuximab and savolitinib
- Sponsor
- Yale University
Colorectal Cancer, Metastatic Colorectal Cancer
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
This study is a prospective, randomized phase III, to evaluate if in patients with mCRC RAS/BRAF wild type on tumor tissue and RAS mutations on liquid biopsy, treating in first line with antibody anti-VEGF (bevacizumab) plus…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation
- Trial name
- LIBImAb (NCT04776655)
- Testing
- Bevacizumab, Cetuximab, 5-FU
- Where
- 4 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Colorectal Cancer
The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody
Establishing the genetic map of primary and secondary resistance of Chinese wild RAS colorectal cancer received anti-EGFR treatment through tissues and peripheral blood NGS testing.
- Trial name
- NCT04466267
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Multicentric randomised trial. The goal of this clinical research study is to evaluate the efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of pMMR/Ras/BRAF wild-type unresectable peritoneal…
- Trial name
- NCT05742425
- Testing
- Serplulimab Combined With FOLFIRI and Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
The study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab®…
- Trial name
- NCT03391934
- Testing
- Cetuximab + FOLFIRI
- Where
- Iran
- Volunteers
- 234 people
- Sponsor
- Cinnagen
Colorectal Cancer
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients…
- Trial name
- DEBIRITUX (NCT01060423)
- Testing
- Cetuximab, Irinotecan, Irinotecan eluting BEADS
- Where
- 13 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Hans-Joachim Schmoll, MD
Colorectal Cancer
A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.
- Trial name
- DEEPER (NCT02515734)
- Testing
- fluorouracil, Leucovorin, irinotecan
- Volunteers
- 360 people
- Sponsor
- Japan Clinical Cancer Research Organization
Metastatic Colorectal Cancer (CRC)
Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
This study aims to evaluate the effectiveness and safety of combining fruquintinib (an oral anti-angiogenesis drug) with cetuximab-beta (an anti-EGFR antibody) in patients with RAS wild-type metastatic colorectal cancer who have…
- Trial name
- NCT07724223
- Testing
- Fruquintinib plus Cetuximab-beta
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, CRC
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06445062
- Testing
- RMC-6236, mFOLFOX6 regimen, bevacizumab
- Where
- 32 sites in United States
- Volunteers
- 1,130 people
- Sponsor
- Revolution Medicines, Inc.
Colorectal Cancer Metastatic
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
The objective of this clinical trial is to evaluate the efficacy and safety of cetuximab combined with PD-1 inhibitor and irinotecan in negative ultraselection RAS/BRAF wild-type refractory right-sided metastatic colorectal…
- Trial name
- NCT06547203
- Testing
- Cetuximab, Toripalimab, Irinotecan
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
The investigators hypothesize that the epigenetic agent valproic acid improve the activity of anti-EGFR agents, prevent and revert the emergence of EGFR resistance, in a rechallenge setting.
- Trial name
- VICTORIA (NCT06714357)
- Testing
- irinotecan, panitumumab, Valproic Acid (VPA)
- Where
- 8 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Colo-rectal Cancer, Capecitabine
First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes
This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF…
- Conditions
- Colo-rectal Cancer, Capecitabine, Cetuximab
- Trial name
- CAPCET (NCT05022030)
- Testing
- mCapOX plus cetuximab, mFOLFOX6 plus cetuximab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- West China Hospital
Metastatic Colon Cancer
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at…
- Trial name
- VELO (NCT05468892)
- Testing
- Trifluridine Tipiracil, Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
- Where
- 8 sites in Italy
- Volunteers
- 68 people
- Sponsor
- University of Campania Luigi Vanvitelli
Colorectal Cancer
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
The association of doublet chemotherapy (FOLFOX and FOLFIRI) and anti-EGFR-moAbs (panitumumab or cetuximab) is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients, especially with…
- Trial name
- PARERE (NCT04787341)
- Testing
- Regorafenib, Panitumumab
- Where
- Italy
- Volunteers
- 213 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival.
- Trial name
- AIO-KRK-0114 (NCT02934529)
- Testing
- Irinotecan, Folinic Acid, 5-FU
- Where
- Germany
- Volunteers
- 673 people
- Sponsor
- Ludwig-Maximilians - University of Munich